Drug Type Small molecule drug |
Synonyms Cloverine, 클로베린정 |
Target |
Action inhibitors, antagonists |
Mechanism PDE10A inhibitors(Phosphodiesterase 10A inhibitors), mAChRs antagonists(Muscarinic acetylcholine receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (22 Mar 2022), |
Regulation- |
Molecular FormulaC19H35NO2 |
InChIKeyCURUTKGFNZGFSE-UHFFFAOYSA-N |
CAS Registry77-19-0 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Abdominal Pain | South Korea | 22 Mar 2022 | |
| Colic | South Korea | 22 Mar 2022 | |
| Gastralgia | South Korea | 22 Mar 2022 | |
| Heartburn | South Korea | 22 Mar 2022 | |
| Hyperchlorhydria | South Korea | 22 Mar 2022 |





